Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

Cancer Cell

Volumn 21, Issue 4, 2012, Pages 504-516

  Dapito, Dianne H ^a,b   Mencin, Ali ^b   Gwak, Geum Youn ^a,c   Pradere, Jean Philippe ^a   Jang, Myoung Kuk ^a   Mederacke, Ingmar ^a   Caviglia, Jorge M ^a   Khiabanian, Hossein ^b   Adeyemi, Adebowale ^b   Bataller, Ramon ^d   Lefkowitch, Jay H ^b   Bower, Maureen ^e   Friedman, Richard ^b   Sartor, R Balfour ^e   Rabadan, Raul ^b   Schwabe, Robert F ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIREGULIN; RIFAXIMIN; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE FLORA; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84859812538     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.02.007     Document Type: Article

References (48)

1. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
2. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B., Sigal S., Sheikh M.Y., Beavers K., Frederick T., et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 2010, 362:1071-1081.
3. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., Weber A., Weiskirchen R., Liedtke C., Gassler N., et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
4. Brandl K., Sun L., Neppl C., Siggs O.M., Le Gall S.M., Tomisato W., Li X., Du X., Maennel D.N., Blobel C.P., Beutler B. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc. Natl. Acad. Sci. USA 2010, 107:19967-19972.
5. Broitman S.A., Gottlieb L.S., Zamcheck N. Influence of neomycin and ingested endotoxin in the pathogenesis of choline deficiency cirrhosis in the adult rat. J. Exp. Med. 1964, 119:633-642.
6. Brooling J.T., Campbell J.S., Mitchell C., Yeoh G.C., Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. Hepatology 2005, 41:906-915.
7. Bruix J., Boix L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
8. Cirera I., Bauer T.M., Navasa M., Vila J., Grande L., Taurá P., Fuster J., García-Valdecasas J.C., Lacy A., Suárez M.J., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J. Hepatol. 2001, 34:32-37.
9. Cober M.P., Johnson C.E., Lee J., Currie K. Stability of extemporaneously prepared rifaximin oral suspensions. Am. J. Health Syst. Pharm. 2010, 67:287-289.
10. Dolganiuc A., Norkina O., Kodys K., Catalano D., Bakis G., Marshall C., Mandrekar P., Szabo G. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007, 133:1627-1636.
11. Engelhardt N.V., Factor V.M., Yasova A.K., Poltoranina V.S., Baranov V.N., Lasareva M.N. Common antigens of mouse oval and biliary epithelial cells. Expression on newly formed hepatocytes. Differentiation 1990, 45:29-37.
12. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5, Suppl. 1):S35-S50.
13. Fukata M., Chen A., Vamadevan A.S., Cohen J., Breglio K., Krishnareddy S., Hsu D., Xu R., Harpaz N., Dannenberg A.J., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133:1869-1881.
14. Fukui H., Brauner B., Bode J.C., Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J. Hepatol. 1991, 12:162-169.
15. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
16. Hatano E., Bennett B.L., Manning A.M., Qian T., Lemasters J.J., Brenner D.A. NF-kappaB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis. Gastroenterology 2001, 120:1251-1262.
17. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., Bremer J., Iezzi G., Graf R., Clavien P.A., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
18. He G., Yu G.Y., Temkin V., Ogata H., Kuntzen C., Sakurai T., Sieghart W., Peck-Radosavljevic M., Leffert H.L., Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010, 17:286-297.
19. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., Gupta S., Moore J., Wrobel M.J., Lerner J., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:1995-2004.
20. Hsu D., Fukata M., Hernandez Y.G., Sotolongo J.P., Goo T., Maki J., Hayes L.A., Ungaro R.C., Chen A., Breglio K.J., et al. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab. Invest. 2010, 90:1295-1305.
21. Inokuchi S., Aoyama T., Miura K., Osterreicher C.H., Kodama Y., Miyai K., Akira S., Brenner D.A., Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. USA 2010, 107:844-849.
22. Kluwe J., Pradere J.P., Gwak G.Y., Mencin A., De Minicis S., Osterreicher C.H., Colmenero J., Bataller R., Schwabe R.F. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010, 138:347-359.
23. Lee S.H., Hu L.L., Gonzalez-Navajas J., Seo G.S., Shen C., Brick J., Herdman S., Varki N., Corr M., Lee J., Raz E. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat. Med. 2010, 16:665-670.
24. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
25. Lin R.S., Lee F.Y., Lee S.D., Tsai Y.T., Lin H.C., Lu R.H., Hsu W.C., Huang C.C., Wang S.S., Lo K.J. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 1995, 22:165-172.
26. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
27. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:108-118.
28. Machida K., Tsukamoto H., Mkrtchyan H., Duan L., Dynnyk A., Liu H.M., Asahina K., Govindarajan S., Ray R., Ou J.H., et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc. Natl. Acad. Sci. USA 2009, 106:1548-1553.
29. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
30. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
31. Nolan J.P., Leibowitz A.I. Endotoxins in liver disease. Gastroenterology 1978, 75:765-766.
32. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
33. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
34. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
35. Rutenburg A.M., Sonnenblick E., Koven I., Aprahamian H.A., Reiner L., Fine J. The role of intestinal bacteria in the development of dietary cirrhosis in rats. J. Exp. Med. 1957, 106:1-14.
36. Sakata H., Takayama H., Sharp R., Rubin J.S., Merlino G., LaRochelle W.J. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 1996, 7:1513-1523.
37. Samuel M.S., Lopez J.I., McGhee E.J., Croft D.R., Strachan D., Timpson P., Munro J., Schröder E., Zhou J., Brunton V.G., et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011, 19:776-791.
38. Santoni-Rugiu E., Preisegger K.H., Kiss A., Audolfsson T., Shiota G., Schmidt E.V., Thorgeirsson S.S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 1996, 93:9577-9582.
39. Schuppan D., Afdhal N.H. Liver cirrhosis. Lancet 2008, 371:838-851.
40. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., Schwabe R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13:1324-1332.
41. Seki E., De Minicis S., Gwak G.Y., Kluwe J., Inokuchi S., Bursill C.A., Llovet J.M., Brenner D.A., Schwabe R.F. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 2009, 119:1858-1870.
42. Takami T., Kaposi-Novak P., Uchida K., Gomez-Quiroz L.E., Conner E.A., Factor V.M., Thorgeirsson S.S. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 2007, 67:9844-9851.
43. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin. Liver Dis. 2008, 28:26-42.
44. Toyoda H., Komurasaki T., Uchida D., Takayama Y., Isobe T., Okuyama T., Hanada K. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 1995, 270:7495-7500.
45. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., Sitaraman S.V., Knight R., Ley R.E., Gewirtz A.T. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
46. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
47. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-433.
48. Yu L.X., Yan H.X., Liu Q., Yang W., Wu H.P., Dong W., Tang L., Lin Y., He Y.Q., Zou S.S., et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010, 52:1322-1333.